Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS North America Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Preview AMS TV
Features
AMS Features
News & Publications
AMS Bookstore
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Disease response and patient-reported outcomes among initiators of ixekizumab
By
- AMS
posted
Dec 03, 2020 06:01 AM
0
Recommend
.
0 comments
0 views
Permalink
Related Content
Ixekizumab and ustekinumab in psoriasis: post-hoc comparison of onset and duration of treatment response
- AMS
Added Jun 26, 2020
Blog Entry
Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials
- AMS
Added Nov 23, 2020
Blog Entry
Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumab
- AMS
Added Sep 22, 2021
Blog Entry
Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events
- AMS
Added Apr 22, 2020
Blog Entry
Microneedling Plus Topical Pimecrolimus Show Positive Outcomes in Vitiligo Care
- AMS
Added Jan 05, 2022
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic